Chiasma, Inc. is a commercial-stage biopharmaceutical company specializing in oral formulations of peptide and protein drugs using its proprietary Transient Permeability Enhancer (TPE™) technology.[1][2][3][4] It develops products that convert injectable therapies to oral versions, such as Mycapssa, the first FDA-approved oral somatostatin analog capsule for acromegaly, targeting patients with rare chronic diseases by improving treatment convenience and potentially reducing side effects.[1][2][3] The company serves patients facing injection-related challenges, solving key problems in drug delivery for peptides, with demonstrated growth through $185.8M in total funding across three rounds, including a $75M recent raise, and partnerships like Merck recognizing its oral peptide potential.[1][2]
Chiasma emerged as a biopharma innovator focused on proprietary technology to reformulate approved drugs into oral forms, enabling switches from injectables and exploring new indications.[2][3][4] Headquartered in Newton Center, Massachusetts, with around 106 employees and revenue under $5M, it built early traction by advancing TPE™ for peptide delivery, culminating in Mycapssa's approval as a pioneering oral therapy for acromegaly.[1][2][3] Pivotal moments include securing substantial funding and industry validation, positioning it to address unmet needs in rare disease treatments, though specific founders or exact founding year details are not detailed in available records.[2][5]
Chiasma rides the trend toward oral peptide therapeutics in biopharma, addressing the $100B+ injectable peptide market by enabling patient-friendly alternatives amid rising demand for convenient chronic disease management.[1][2][3] Timing aligns with FDA approvals for novel formulations and investor interest in rare disease drugs, bolstered by market forces like aging populations and injection fatigue.[1][4][5] It influences the ecosystem by pioneering TPE™, inspiring similar tech in women's health and beyond, while contributing to startup growth through experienced leadership in drug development and manufacturing.[1]
Chiasma is poised to expand its TPE™ pipeline into additional rare diseases and partnerships, leveraging Mycapssa's success amid surging oral biologics demand.[1][2] Trends like AI-driven drug discovery and peptide market growth to $50B+ by 2030 will shape its path, potentially amplifying influence through acquisitions or broader licensing.[1][3] As biopharma shifts to accessible therapies, Chiasma's injectable-to-oral pivot positions it as a key innovator, building on its funding momentum for sustained impact.
Chiasma has raised $161.0M in total across 4 funding rounds.
Chiasma's investors include Abingworth, ARCH Venture Partners, MPM Capital, Norwest Venture Partners, Pureos Bioventures.
Chiasma has raised $161.0M across 4 funding rounds. Most recently, it raised $70.0M Series E in February 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2015 | $70.0M Series E | Abingworth, ARCH Venture Partners, MPM Capital, Norwest Venture Partners, Pureos Bioventures | |
| Jul 1, 2012 | $39.0M Series D | Abingworth, ARCH Venture Partners, MPM Capital, Norwest Venture Partners, Pureos Bioventures | |
| Nov 1, 2006 | $44.0M Series C | Abingworth, ARCH Venture Partners, MPM Capital, Norwest Venture Partners, Pureos Bioventures | |
| Sep 1, 2005 | $8.0M Series B | Abingworth, ARCH Venture Partners, MPM Capital |
